Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and
have a key role in the epigenetic regulation of gene expression. In addition, the activity of …

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor.
The majority of patients with metastatic breast cancer who initially respond to trastuzumab …

Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in
preclinical studies for multiple myeloma (MM) cells. LBH589 is a novel hydroxamic acid …

Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer
treatment as many HDAC inhibitors have entered clinical trials for both solid and liquid …

The molecular chaperone heat shock protein 90 (HSP90) has emerged as an exciting
molecular target for cancer therapy. It operates as part of a multichaperone complex and is …

Acetylation and deacetylation of chromatin histone protein by histone deacetylase (HDAC)
alters chromatin structure and dynamically affects transcriptional regulation. Many lines of …

Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the
current investigation, we examined the activity of PXD101, a potent histone deacetylase …

AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent in vitro and in vivo
activity against the unmutated and most common mutant forms of Bcr-Abl. Treatment with the …

According to the concept of immune surveillance, the appearance of a tumor indicates that it
has earlier evaded host defenses and subsequently must have escaped immunity to evolve …

Raf kinase signaling has been thoroughly investigated over the last 20 years. A‐Raf, B‐Raf
and C‐Raf, the 3 mammalian members of the Raf family, are involved in a variety of cellular …